• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

miRNAs 在胰腺癌进展和转移中的作用。

miRNAs in pancreatic cancer progression and metastasis.

机构信息

Matrix & Metastasis Lab, Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.

School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.

出版信息

Clin Exp Metastasis. 2024 Jun;41(3):163-186. doi: 10.1007/s10585-023-10256-0. Epub 2024 Jan 19.

DOI:10.1007/s10585-023-10256-0
PMID:38240887
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11213741/
Abstract

Small non-coding RNA or microRNA (miRNA) are critical regulators of eukaryotic cells. Dysregulation of miRNA expression and function has been linked to a variety of diseases including cancer. They play a complex role in cancers, having both tumour suppressor and promoter properties. In addition, a single miRNA can be involved in regulating several mRNAs or many miRNAs can regulate a single mRNA, therefore assessing these roles is essential to a better understanding in cancer initiation and development. Pancreatic cancer is a leading cause of cancer death worldwide, in part due to the lack of diagnostic tools and limited treatment options. The most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is characterised by major genetic mutations that drive cancer initiation and progression. The regulation or interaction of miRNAs with these cancer driving mutations suggests a strong link between the two. Understanding this link between miRNA and PDAC progression may give rise to novel treatments or diagnostic tools. This review summarises the role of miRNAs in PDAC, the downstream signalling pathways that they play a role in, how these are being used and studied as therapeutic targets as well as prognostic/diagnostic tools to improve the clinical outcome of PDAC.

摘要

小非编码 RNA 或 microRNA (miRNA) 是真核细胞的关键调控因子。miRNA 表达和功能的失调与多种疾病有关，包括癌症。它们在癌症中发挥着复杂的作用，既有肿瘤抑制因子又有促进因子的特性。此外，单个 miRNA 可以参与调节多个 mRNAs，或者许多 miRNA 可以调节单个 mRNA，因此评估这些作用对于更好地理解癌症的发生和发展至关重要。

胰腺癌是全球癌症死亡的主要原因之一，部分原因是缺乏诊断工具和有限的治疗选择。最常见的胰腺癌形式，胰腺导管腺癌 (PDAC)，其特征是主要的遗传突变，这些突变驱动癌症的发生和进展。miRNA 与这些致癌突变的调节或相互作用表明它们之间存在很强的联系。了解 miRNA 与 PDAC 进展之间的这种联系可能会产生新的治疗方法或诊断工具。

这篇综述总结了 miRNA 在 PDAC 中的作用、它们在其中发挥作用的下游信号通路、如何将它们作为治疗靶点以及作为预后/诊断工具来改善 PDAC 的临床结果进行研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/e0500c3d1f50/10585_2023_10256_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/f2d258059349/10585_2023_10256_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/c9a7362eb7d7/10585_2023_10256_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/6b6191b18720/10585_2023_10256_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/e0500c3d1f50/10585_2023_10256_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/f2d258059349/10585_2023_10256_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/c9a7362eb7d7/10585_2023_10256_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/6b6191b18720/10585_2023_10256_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ad/11213741/e0500c3d1f50/10585_2023_10256_Fig4_HTML.jpg

相似文献

1
miRNAs in pancreatic cancer progression and metastasis.miRNAs 在胰腺癌进展和转移中的作用。
Clin Exp Metastasis. 2024 Jun;41(3):163-186. doi: 10.1007/s10585-023-10256-0. Epub 2024 Jan 19.
2
MicroRNA in pancreatic cancer.胰腺癌中的微小RNA
J Hum Genet. 2017 Jan;62(1):33-40. doi: 10.1038/jhg.2016.59. Epub 2016 Jun 2.
3
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.用于胰腺导管腺癌细胞中 microRNA 表达和功能分析的资源。
Cancer Biol Ther. 2009 Nov;8(21):2013-24. doi: 10.4161/cbt.8.21.9685.
4
Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.miRNAs 靶向调控胰腺导管腺癌中 IGF-1R 通路的失调。
Cells. 2021 Jul 22;10(8):1856. doi: 10.3390/cells10081856.
5
Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.巨噬细胞衍生的外泌体 microRNA-501-3p 通过 TGFBR3 介导的 TGF-β 信号通路促进胰腺导管腺癌的进展。
J Exp Clin Cancer Res. 2019 Jul 15;38(1):310. doi: 10.1186/s13046-019-1313-x.
6
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma.微小 RNA-21 的敲低通过靶向程序性细胞死亡 4（PDCD4）抑制胰腺导管腺癌的增殖并增加细胞死亡。
J Gastrointest Surg. 2011 Jan;15(1):199-208. doi: 10.1007/s11605-010-1381-x. Epub 2010 Nov 19.
7
Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.通过加权基因共表达网络分析鉴定胰腺导管腺癌的候选 miRNA 生物标志物
Cell Oncol (Dordr). 2017 Apr;40(2):181-192. doi: 10.1007/s13402-017-0315-y. Epub 2017 Feb 15.
8
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.微小RNA-323-3p通过直接抑制SMAD2和SMAD3抑制胰腺导管腺癌的细胞侵袭和转移。
Oncotarget. 2016 Mar 22;7(12):14912-24. doi: 10.18632/oncotarget.7482.
9
The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.miRNA-218 和 ROBO-1 信号轴与胰腺癌的淋巴转移相关。
Oncol Rep. 2013 Aug;30(2):651-8. doi: 10.3892/or.2013.2516. Epub 2013 Jun 3.
10
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?胰腺癌中的微小RNA：预测/预后生物标志物还是治疗靶点？
Oncotarget. 2015 Sep 15;6(27):23323-41. doi: 10.18632/oncotarget.4492.

引用本文的文献

1
Human multiethnic radiogenomics reveals low-abundancy microRNA signature in plasma-derived extracellular vesicles for early diagnosis and molecular subtyping of pancreatic cancer.人类多民族放射基因组学揭示了血浆来源的细胞外囊泡中低丰度微小RNA特征，用于胰腺癌的早期诊断和分子亚型分类。
Elife. 2025 Aug 8;14:RP103737. doi: 10.7554/eLife.103737.
2
Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications.胰腺癌中的新兴肿瘤生物标志物及其临床意义
Curr Issues Mol Biol. 2025 May 10;47(5):347. doi: 10.3390/cimb47050347.
3
Bio-engineered microRNA-7 effectively interferes with the Akt3/p53 axis to suppress human non-small cell lung cancer.

本文引用的文献

1
Circulating miRNAs as Noninvasive Biomarkers for PDAC Diagnosis and Prognosis in Mexico.循环 miRNA 作为墨西哥 PDAC 诊断和预后的非侵入性生物标志物。
Int J Mol Sci. 2023 Oct 14;24(20):15193. doi: 10.3390/ijms242015193.
2
SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis.SCARA5在前列腺癌中过表达并与预后不良相关。
Diagnostics (Basel). 2023 Jun 29;13(13):2211. doi: 10.3390/diagnostics13132211.
3
Circulating tumour cells for early detection of clinically relevant cancer.循环肿瘤细胞用于早期检测临床相关癌症。
生物工程改造的微小RNA-7有效干扰Akt3/p53轴以抑制人类非小细胞肺癌。
Cancer Cell Int. 2025 Jul 2;25(1):250. doi: 10.1186/s12935-025-03856-1.
4
Molecular Insights into HPV-Driven Cervical Cancer: Oncoproteins, Immune Evasion, and Epigenetic Modifications.人乳头瘤病毒驱动的宫颈癌的分子见解：癌蛋白、免疫逃逸和表观遗传修饰
Microorganisms. 2025 Apr 27;13(5):1000. doi: 10.3390/microorganisms13051000.
5
Polyphenols and miRNA interplay: a novel approach to combat apoptosis and inflammation in Alzheimer's disease.多酚与微小RNA的相互作用：对抗阿尔茨海默病细胞凋亡和炎症的新方法。
Front Aging Neurosci. 2025 May 7;17:1571563. doi: 10.3389/fnagi.2025.1571563. eCollection 2025.
6
miRNA profile in pancreatic neuroendocrine tumors: Preliminary results.胰腺神经内分泌肿瘤中的微小RNA谱：初步结果。
Sci Prog. 2025 Jan-Mar;108(1):368504251326864. doi: 10.1177/00368504251326864. Epub 2025 Mar 28.
7
Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.遗传性胰腺癌：基因检测、早期检测策略及个性化管理的进展
J Clin Med. 2025 Jan 9;14(2):367. doi: 10.3390/jcm14020367.
8
A Dual-Cycle Isothermal Amplification Method for microRNA Detection: Combination of a Duplex-Specific Nuclease Enzyme-Driven DNA Walker with Improved Catalytic Hairpin Assembly.一种用于微小RNA检测的双循环等温扩增方法：双链特异性核酸酶驱动的DNA步行器与改进的催化发夹组装相结合
Int J Mol Sci. 2025 Jan 15;26(2):689. doi: 10.3390/ijms26020689.
9
Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.微小RNA在胰腺癌中的诊断和预后准确性：一项系统评价和荟萃分析
J Cell Mol Med. 2025 Jan;29(2):e70337. doi: 10.1111/jcmm.70337.
10
Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.解读非编码RNA在脂肪肉瘤发生发展中的作用：转化治疗进展面临的挑战与机遇
Noncoding RNA Res. 2024 Nov 15;11:73-90. doi: 10.1016/j.ncrna.2024.11.005. eCollection 2025 Apr.
Nat Rev Clin Oncol. 2023 Jul;20(7):487-500. doi: 10.1038/s41571-023-00781-y. Epub 2023 Jun 2.
4
EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?癌症中的 EMT/MET 可塑性与静止期的 Go-or-Grow 决策：同一枚硬币的两面？
Mol Cancer. 2023 May 31;22(1):90. doi: 10.1186/s12943-023-01793-z.
5
miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.血浆小细胞外囊泡中的 miR-18a 和 miR-106a 特征可作为胰腺导管腺癌早期检测的有前途的生物标志物。
Int J Mol Sci. 2023 Apr 13;24(8):7215. doi: 10.3390/ijms24087215.
6
Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma.失调的微小RNA调节胰腺导管腺癌中与肿瘤微环境相关的信号网络。
Precis Clin Med. 2023 Mar 10;6(1):pbad004. doi: 10.1093/pcmedi/pbad004. eCollection 2023 Mar.
7
Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study.外泌体 miRNA 生物标志物panel 用于患者血浆中胰腺导管腺癌的检测：一项初步研究。
Int J Mol Sci. 2023 Mar 7;24(6):5081. doi: 10.3390/ijms24065081.
8
KRAS Hijacks the miRNA Regulatory Pathway in Cancer.KRAS 劫持癌症中的 miRNA 调控途径。
Cancer Res. 2023 May 15;83(10):1563-1572. doi: 10.1158/0008-5472.CAN-23-0296.
9
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.用于II期和III期结直肠癌基于FOLFOX辅助治疗的风险分层和反应预测的微小RNA特征。
Mol Cancer. 2023 Jan 20;22(1):13. doi: 10.1186/s12943-022-01699-2.
10
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.